InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Prescient Therapeutics Limited (ASX:PTX)

ALERT: Price-sensitive ASX Announcement for PTX
Current share price for PTX : $0.066 -0.006 (-8.33%)+
Announcement
Release
25 Aug 2026 9:06AM
Price at Release
$0.072
Full Release
download
Summary
Prescient Therapeutics Limited (ASX: PTX), an Australian clinical-stage oncology company, has announced a Share Purchase Plan (SPP) targeting to raise $7 million. The shares will be offered at $0.065 each, representing an 18.8% discount to the volume-weighted average price over the preceding 10 trading days. The funds are intended to support the development of PTX-100, an innovative cancer treatment, and its progression through the Dose Optimisation Committee review scheduled for later in 2026, as well as general corporate purposes. The SPP is open to eligible shareholders registered by 24th August 2026, and the results will be announced on 14th September 2026, with share allotment expected by 15th September 2026. Prescient's CEO, James McDonnell, will provide further details in a shareholder briefing scheduled for 28th August 2026.
Key Points
  • Share Purchase Plan (SPP) aims to raise $7 million.
  • Shares priced at $0.065, an 18.8% discount to the 10-day VWAP.
  • Funds to be used for PTX-100 development and corporate purposes.
  • Key dates include a shareholder briefing on 28th August 2026.
  • SPP open to shareholders registered by 24th August 2026.
  • Results announced on 14th September 2026, allotment on 15th September 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.